< 1 minute read
Dec. 10, 2021

Repotrectinib (TPX-0005): A Brain-Penetrant Macrocyclic ALK/ROS1/TRK Kinase Inhibitor

repotrectinib

oral, CNS-penetrant TRK(A-C) kinase inhibitor Ph. II candidate for solid tumors (160 mg QD), approved 2023 from literature starting point Molecular Cancer Therapeutics Turning Point Therapeutics, San Diego, CA

twitterlinkedinprintemail